Alnylam Pharmaceuticals’ new cardiovascular drug is off to a stronger-than-expected launch.
The treatment, Amvuttra, brought in $492 million in the second quarter, the biotech said Thursday, beating the $351 million expected by analysts polled by Visible Alpha.
Amvuttra has been approved to treat a rare nerve condition for several years, but was also cleared in March as a treatment for a more common heart disease called transthyretin amyloid cardiomyopathy, or ATTR-CM. The sales number covers both indications.
